Ambalal Sarabhai Enterprises Limited (NSE:AMBALALSA)

India flag India · Delayed Price · Currency is INR
31.94
-0.21 (-0.65%)
At close: Jun 19, 2026
Market Cap2.44B -16.0%
Revenue (ttm)2.02B +2.5%
Net Income178.04M +261.0%
EPS2.32 +262.5%
Shares Out n/a
PE Ratio13.69
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume110,381
Open32.69
Previous Close32.15
Day's Range31.50 - 32.69
52-Week Range30.30 - 38.50
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 10, 2026

About NSE:AMBALALSA

Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company offers products for oncology, infertility, and uro-gynaec areas; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients. It also provides broadcast and professional video/audio, and electronic products. Am... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 547
Stock Exchange National Stock Exchange of India
Ticker Symbol AMBALALSA
Full Company Profile

Financial Performance

In fiscal year 2026, NSE:AMBALALSA's revenue was 2.02 billion, an increase of 2.50% compared to the previous year's 1.97 billion. Earnings were 178.04 million, an increase of 261.05%.

Financial Statements

News

EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity

Co-Diagnostics Inc. (NASDAQ: CODX) on Friday signed an agreement for CoSara Diagnostics Pvt. Ltd , to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakista...

3 months ago - Benzinga